CTRI/2020/07/026720尚未招募未知
A prospective, randomized, double-blind, placebo-controlled parallel-group clinical trial to evaluate the effects of a Bacillus coagulans-based product in patients with IBS-Diarrhea
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Male or female
- •2.18 - 65 years old
- •3.Signed informed consent
- •4.IBS-Diarrhea patient satisfying Rome III criteria.
- •oRecurrent abdominal pain or discomfort, 3 days per month in the last 3 months (12 weeks), associated with >= 2 of the criteria below. The criteria are fulfilled with symptoms onset 6 months prior to diagnosis:
排除标准
- •1. The patient will be excluded from the study if assessment by the treating investigator showed an evidence for cardiovascular, respiratory, urogenital, gastrointestinal/hepatic, hematologic/immunologic, head, ears, eyes, nose and throat, dermatologic/psychiatric, allergy, major surgery or other diseases as revealed by history, physical examination and existing laboratory assessments which may interfere with the administration.
- •2.Pregnant or lactating women.
- •3.Females at childbearing age will be excluded unless they are using acceptable birth control measures (i.e. implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices, sexual abstinence or a vasectomized partner).
- •4.Patients requiring treatments with non-permitted medication (i.e. 5-HT3 antagonist, spasmolytics, anticholinergics, cholestyramine, anti flatulence agents, metoclopramide, gastric-anti secretory agents (proton pump inhibitors; for indications other than Gastroesophageal Reflux Disease (GERD)), narcotics, anti-diarrheal drugs, and systemic steroids)
- •5.Patients requiring the use of antibiotics either in medicine form of natural (e.g. grapefruit seed extract, olive leaf extract, oil of oregano, colloidal silver and highly concentrated garlic preparations)
- •6. Exercise and the use of complementary and alternative medicine for IBS symptoms (i.e. peppermint oil, cognitive behavior therapy) during the study should be maintained at the same level prior to the study.
- •7.Patients exceeding the treatment limits of permitted medication [(more than 2 days/week during the study period): alginate, antacids and analgesics (limited to acetaminophen <= 1000 mg/day, acetylsalicylic acid or NSAIDS no more than 2 tablets/day), (stable dose throughout the study period, anti-depressants (must be on a stable dose > 3 months), fiber supplements, psyllium hydrophilic mucilloid, gastric anti secretory agents (only for GERD patients who are on a stable dose > 3 months; patients should be able to differentiate between IBS and GERD symptoms), acetylsalicylic acid <= 325 mg/day, sedatives. Deliverance medications: Mild laxatives only if necessary.]. Any other medications can be used without limits based on the clinical judgment of the treating investigator.
- •8.Being in another clinical trial 4 weeks before entering the study
- •9.Constipated IBS patients
- •10.IBS-Diarrhea patients with un-treated lactose intolerance
- •11.Regular use of probiotics or using other probiotics during the course of the study
- •12.Patients allergic to milk or soy products
- •13.Patients using catheters
- •14.Patients presented with rectal bleeding, weight loss, iron deficiency anemia, nocturnal symptoms and a family history of colorectal cancer, inflammatory bowel disease and celiac spruce
- •15.Patients over 50 diagnosed with Irritable Bowel Syndrome who have not had a colonoscopy in the last 5 years
- •16.Patients who have allergies for the active ingredients or any of the excipients
- •17.Patients presented with any immune-compromised condition (such as AIDS, lymphoma, long term corticosteroid treatment)
- •Patients presented with nausea, vomiting and fever.
研究者
相似试验
尚未招募
2 期
To evaluate the effectiveness of DigeSEB Super PB on digestion and gastrointestinal symptoms in healthy adultsCTRI/2023/10/058902Advanced Enzyme Technologies Ltd
尚未招募
不适用
Beta-alanine supplementation in patients with COPD receiving non-linear periodized exercise (NLPE) training: randomized placebo-controlled trial.Chronic obstructive pulmonary disease (COPD)Exercise intoleranceMuscle dysfunction.NL-OMON23943Radboudumc Board of Directors154
进行中（未招募）
1 期
A prospective, randomized, double-blind, placebo-controlled, international, multicentre, parallel-group comparison trial evaluating the efficacy and safety of single i.v. bolus tenecteplase plus standard anticoagulation as compared with standard anticoagulation in normotensive patients with acute pulmonary embolism and with echocardiographic (or spiral CT) and laboratory evidence of right ventricular dysfunction. - PEITHOPatients suffered from acut pulmonary embolism.EUCTR2006-005328-18-HUAssistance Publique - Hôpitaux de Paris (AP-HP)1,000
进行中（未招募）
不适用
Study with two injections (one injection with placebo or drug, one injection with drug) to investigate the efficacy and safety of NT 201 (active ingredient: Botulinum (neuro)toxin type A, free from complexing proteins) in the combined treatment of wrinkles in the upper face.pper facial lines (horizontal forehead lines, glabellar frown lines, and lateral periorbital lines)MedDRA version: 14.1Level: PTClassification code 10040954Term: Skin wrinklingSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2011-005887-20-DEMerz Pharmaceuticals GmbH150
进行中（未招募）
1 期
Study with two injections (one injection with placebo or drug, one injectionwith drug) to investigate the efficacy and safety of NT 201 (activeingredient: Botulinum (neuro)toxin type A, free from complexing proteins)in the combined treatment of wrinkles in the upper face.pper facial lines (horizontal forehead lines, glabellar frown lines, and lateral periorbital lines)MedDRA version: 15.0Level: PTClassification code 10040954Term: Skin wrinklingSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2011-005887-20-GBMerz Pharmaceuticals GmbH156